These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
440 related articles for article (PubMed ID: 33809369)
1. Investigating T Cell Immunity in Cancer: Achievements and Prospects. Zeng Z; Chew HY; Cruz JG; Leggatt GR; Wells JW Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33809369 [TBL] [Abstract][Full Text] [Related]
2. Cytotoxic CD8 Iwahori K Adv Exp Med Biol; 2020; 1224():53-62. PubMed ID: 32036604 [TBL] [Abstract][Full Text] [Related]
3. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells. Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085 [TBL] [Abstract][Full Text] [Related]
4. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Finn OJ Ann Oncol; 2012 Sep; 23 Suppl 8(Suppl 8):viii6-9. PubMed ID: 22918931 [TBL] [Abstract][Full Text] [Related]
7. Enhancing tumor T cell infiltration to enable cancer immunotherapy. Zhang J; Endres S; Kobold S Immunotherapy; 2019 Feb; 11(3):201-213. PubMed ID: 30730277 [TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes. Sun NY; Chen YL; Lin HW; Chiang YC; Chang CF; Tai YJ; Chen CA; Sun WZ; Chien CL; Cheng WF Cancer Lett; 2019 Mar; 444():20-34. PubMed ID: 30543813 [TBL] [Abstract][Full Text] [Related]
9. Chimeric Antigen Receptors for the Tumour Microenvironment. Habib R; Nagrial A; Micklethwaite K; Gowrishankar K Adv Exp Med Biol; 2020; 1263():117-143. PubMed ID: 32588326 [TBL] [Abstract][Full Text] [Related]
10. Modulation of the immune microenvironment by tumor-intrinsic oncogenic signaling. Nguyen KB; Spranger S J Cell Biol; 2020 Jan; 219(1):. PubMed ID: 31816057 [TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoints and CAR-T Cells: The Pioneers in Future Cancer Therapies? Hosseinkhani N; Derakhshani A; Kooshkaki O; Abdoli Shadbad M; Hajiasgharzadeh K; Baghbanzadeh A; Safarpour H; Mokhtarzadeh A; Brunetti O; Yue SC; Silvestris N; Baradaran B Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167514 [TBL] [Abstract][Full Text] [Related]
12. Suppression of murine tumour growth through CD8 Kogo H; Shimizu M; Negishi Y; Uchida E; Takahashi H Immunology; 2017 Jul; 151(3):324-339. PubMed ID: 28294313 [TBL] [Abstract][Full Text] [Related]
13. Tuning cancer fate: the unremitting role of host immunity. Calì B; Molon B; Viola A Open Biol; 2017 Apr; 7(4):. PubMed ID: 28404796 [TBL] [Abstract][Full Text] [Related]
14. Prolonged Persistence of Chimeric Antigen Receptor (CAR) T Cell in Adoptive Cancer Immunotherapy: Challenges and Ways Forward. Jafarzadeh L; Masoumi E; Fallah-Mehrjardi K; Mirzaei HR; Hadjati J Front Immunol; 2020; 11():702. PubMed ID: 32391013 [TBL] [Abstract][Full Text] [Related]
15. Cancer cell-expressed BTNL2 facilitates tumour immune escape via engagement with IL-17A-producing γδ T cells. Du Y; Peng Q; Cheng D; Pan T; Sun W; Wang H; Ma X; He R; Zhang H; Cui Z; Feng X; Liu Z; Zhao T; Hu W; Shen L; Jiang W; Gao N; Martin BN; Zhang CJ; Zhang Z; Wang C Nat Commun; 2022 Jan; 13(1):231. PubMed ID: 35017553 [TBL] [Abstract][Full Text] [Related]
16. CXCL9 chemokine promotes the progression of human pancreatic adenocarcinoma through STAT3-dependent cytotoxic T lymphocyte suppression. Gao HF; Cheng CS; Tang J; Li Y; Chen H; Meng ZQ; Chen Z; Chen LY Aging (Albany NY); 2020 Jan; 12(1):502-517. PubMed ID: 31913856 [TBL] [Abstract][Full Text] [Related]
17. NR4A transcription factors limit CAR T cell function in solid tumours. Chen J; López-Moyado IF; Seo H; Lio CJ; Hempleman LJ; Sekiya T; Yoshimura A; Scott-Browne JP; Rao A Nature; 2019 Mar; 567(7749):530-534. PubMed ID: 30814732 [TBL] [Abstract][Full Text] [Related]
18. Janus or Hydra: The Many Faces of T Helper Cells in the Human Tumour Microenvironment. Guisier F; Barros-Filho MC; Rock LD; Strachan-Whaley M; Marshall EA; Dellaire G; Lam WL Adv Exp Med Biol; 2020; 1224():35-51. PubMed ID: 32036603 [TBL] [Abstract][Full Text] [Related]
19. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies. Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557 [TBL] [Abstract][Full Text] [Related]
20. Dendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment. Fu C; Jiang A Front Immunol; 2018; 9():3059. PubMed ID: 30619378 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]